Chemed Corporation: Short-Term Headwinds But Long-Term Growth Potential
Chemed Corporation's diversified revenue streams from VITAS Healthcare and Roto-Rooter provide a strong competitive advantage and resilience against sector-specific risks. Recent VITAS acquisition ...
CHE Stock Falls Despite Q1 Earnings & Revenue Beat, Gross Margin Declines
Chemed delivers first-quarter top-line growth across two of its segments, VITAS and Roto-Rooter.
Chemed Corporation Declares Quarterly Dividend of 50 Cents
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 50-cents per share on the Company's capital stock, p...
Chemed To Report Fourth-Quarter 2024 Earnings February 26, Related Conference Call To Be Held On February 27
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the fourth quarter ended December 31, 2024, on Wednesday, February 26, 2025, f...
Chemed Corporation Board of Directors Authorizes an Additional $300 Million for Stock Repurchase and Declares Quarterly Dividend of 50 Cents
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has formally authorized an additional $300 million for stock repurchase under Chemed's existin...
CHE Misses on Q3 Earnings, Lowers '24 EPS View, Stock Up
Chemed's VITAS segment reports impressive revenue growth and margin expansion for the third quarter of 2024.
Chemed Remains A Buy On Long-Term Economics
Chemed continues to present with exceptional economic characteristics now at depressed valuations vs. history. The business is highly profitable and earns high rates of return on all the capital th...
Why Chemed (CHE) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Reasons Why Growth Investors Shouldn't Overlook Chemed (CHE)
Chemed (CHE) possesses solid growth attributes, which could help it handily outperform the market.
Should You Keep Chemed (CHE) Stock in Your Portfolio Now?
Chemed's (CHE) robust VITAS business and strong financial stability raise investors' optimism.
Chemed To Report Second-Quarter 2024 Earnings July 24, Related Conference Call To Be Held On July 25
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2024, on Wednesday, July 24, 2024, following...
Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2024
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Securities Health Care Conference 2024 on Tuesday, May 14, 2024...
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.
Chemed (CHE) Q1 Earnings Miss Estimates
Chemed (CHE) came out with quarterly earnings of $5.20 per share, missing the Zacks Consensus Estimate of $5.47 per share. This compares to earnings of $4.82 per share a year ago.
Chemed's (CHE) VITAS Segment Inks New Deal With Covenant Care
Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.
Related Companies